Literature DB >> 9615774

Apoptosis in prostatic adenocarcinomas; a study of relationship to Ki-67 and Bcl-2 protein expression.

N Tanji1, M Yokoyama, T Sugamoto, M Takeuchi, N Terada.   

Abstract

BACKGROUND: Tissue samples from patients with prostatic adenocarcinoma (PCA) were examined for relationship between apoptosis and expression of Ki-67 and bcl-2 protein.
MATERIALS AND METHODS: Prostatic tissue was obtained from 29 prostatic cancer patients with no prior therapy. The number of apoptotic cells (apoptotic index; AI) and the percentage of Ki-67 stained cells (Ki-67 labeling index; LI) were compared with the expression of bcl-2 which was evaluated by the proportion and intensity of tumor cell immunostaining.
RESULTS: Both AI and LI of moderately and poorly differentiated PCAs were significantly higher than those of well differentiated PCAs. There was a significant correlation between AI and LI. Bcl-2 protein was expressed less in moderately and poorly differentiated PCAs than in well differentiated PCAs. Moreover, there was no correlation between the bcl-2 protein expression and the AI.
CONCLUSIONS: The results suggest that, in PCAs, the degree of apoptosis is correlated with the cellular proliferation, and that expression of bcl-2 protein is not a critical factor that determines the degree of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9615774

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer.

Authors:  Zahra Amirghofran; Ahmad Monabati; Naser Gholijani
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

2.  Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.

Authors:  Andrea Vecchione; Tommaso Prayer Galetti; Marina Gardiman; Hideshi Ishii; Enrico Giarnieri; Francesco Pagano; Leonard G Gomella; Carlo M Croce; Raffaele Baffa
Journal:  BMC Urol       Date:  2004-09-09       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.